• Journal of Applied Biological Chemistry
• /
• v.44 no.1
• /
• pp.1-5
• /
• 2001

The methanol extracts of 25 leguminous seeds in vitro was evaluated for inhibitory activities against the small intestinal $\alpha$-glucosidase of Sprague Dawley male rats. The responses varied both with leguminous seed types and concentrations used. At the concentration of 0.5 mg/ml, the methanol extracts of Cassia obtusifolia, Glycine max var. yagkong, Glycine max var. hooktae, Glycine max var. geumdu, Glycine max var. mejukong, Glycine soja, Phaseolus multiflorus, Pisum sativum, and Vigna sinensis inhibited over 50% of the enzyme activity. The extracts of G. max var. yagkong and V. sinensis showed relatively strong inhibitory activities against $\alpha$-glucosidase at the concentration of 0.1 mg/ml. The activity of each solvent fraction from G. max var. yagkong and V. sinensis was determined, and potent activities were detected from chloroform and butanol fractions, respectively. $IC_{50}$ values of G. max var. yagkong and V. sinensis were 0.06 and 0.19 mg/ml, respectively. As a naturally occurring therapeutic agents, leguminous seeds examined could be useful for developing new types of antidiabetic agents.

• 한국전기화학회:학술대회논문집
• /
• 2002.10a
• /
• pp.41-41
• /
• 2002

• Korean Journal of Clinical Pharmacy
• /
• v.8 no.1
• /
• pp.19-22
• /
• 1998

Cefixime is an orally absorbed 3rd generation cephalosporin with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and is highly resistant to $\beta-lactamase$ degradation. This study was carried out to evaluate the bioavailability of a new test drug of cefixime (100 mg/capsule) relative to the reference drug. The bioavailability was conducted on 20 healthy volunteers who received a single dose (400 mg) of the test and the reference drugs in the fasting state, in a randomized balanced 2-way crossover design. After dosing, serial blood samples were collected for a period of 12 hours. Plasma was analyzed for cefixime by a sensitive and validated HPLC assay. The major pharmacokinetic parameters $(AUC_{0-12hr},\;C_{max},\;T_{max})$ were calculated from the plasma concentration-time data of each volunteer. The $AUC_{0-12hr},\;C_{max}\;and\;T_{max}$ of the test drug were $36.91\pm11.85\;{\mu}g{\cdot}hr/ml,\;5.47\pm1.61\;{\mu}g/ml,\;and\;4.00\pm0.65\;hr,$ respectively, and those of the reference drug were $34.08\pm8.81\;{\mu}g{\cdot}hr/ml,\;5.25\pm1.40\;{\mu}g/ml,\;and\;4.20\pm0.62\;hr$, respectively. Mean differences of those parameters were 8.32, 4.29, and $4.76\%$, respectively, and the least significant differences at $\alpha$=0.05 for $AUC_{0-12hr},\;C_{max},\;T_{max}$ were 16.02, 13.78, and $11.76\%$, respectively. In conclusion, the test drug was bioequivalent with the reference drug.

• Journal of Korean Society of Industrial and Systems Engineering
• /
• v.34 no.1
• /
• pp.67-73
• /
• 2011

Using the known result of the expected busy period for a controllable M/G/1 queueing model operating under the triadic Max (N, T, D) policy, its upper and lower bounds are derived to approximate its corresponding actual value. Both bounds are represented in terms of the expected busy periods for the dyadic Min (N, T), Min (N, D) and Min (T, D) and simple N, T and D operating policies. All three input variables N, T and D are equally contributed to construct such bounds for better estimation.

• Journal of Korean Society of Industrial and Systems Engineering
• /
• v.31 no.4
• /
• pp.86-92
• /
• 2008

The expected busy period for the controllable M/G/1 queueing model operating under the triadic Max (N, T, D) policy is derived by using a new concept so called "the pseudo probability density function." In order to justify the proposed approaches for the triadic policy, well-known expected busy periods for the dyadic policies are recovered from the obtained result as special cases.

• Journal of Pharmaceutical Investigation
• /
• v.32 no.1
• /
• pp.47-54
• /
• 2002

Cimetropium bromide, a quaternary ammonium compound which is chemically related to scopolamine, exhibits its antispasmodic activity by competing with acetylcholine for the muscarinic receptors of the smooth muscle of gastrointestinal tract. The drug has been used for the treatment of various disorders involving spasms of the musculature of the gastrointestinal, biliary and genitourinary tracts. The purpose of the present study was to evaluate the bioequivalence of two cimetropium bromide tablets, $Algiron^{TM}$ (Boehringer Ingelheim Korea Ltd.) and $Alpit^{TM}$ (Hana Pharmaceutical Co., Ltd.), according to the prior and revised guidelines of Korea Food and Drug Administration (KFDA). The cimetropium bromide release from the two cimetropium bromide tablets in vitro was tested using KP VII Apparatus II method with various different kinds of dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty normal male volunteers, $25.25{\pm}2.10$ years in age and $65.76{\pm}6.39$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After three tablets containing 50 mg of cimetropium bromide per tablet were orally administered, blood was taken at predetermined time intervals and the concentrations of cimetropium bromide in serum were determined using HPLC method with UV detector. The dissolution profiles of two cimetropium bromide tablets were very similar at all dissolution media. Besides, the pharmacokinetic parameters such as $AUC_t,\;C_{max}\;and\;T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using non-transformed and logarithmically transformed $AUC_t\;and\;C_{max}$. The results showed that the differences in $AUC_t,\;C_{max}\;and\;T_{max}$ between two tablets based on the $Algiron^{TM}$ were 2.19%, -5.97% and 3.49%, respectively. Minimum detectable differences $({\Delta})\;at \;{\alpha}=0.05\;and\;1-{\beta}=0.8$ were less than 20% (e.g., 13.71 %, 19.05% and 15.11% for $AUC_t,\;C_{max}\;and\;T_{max}$, respectively). The powers $(1-{\beta})\;at\;{\alpha}=0.05,\;{\Delta}=0.2\;for\;AUC_t$, $C_{max}\;and\;T_{max}$ were 97.79%, 83.22% and 95.60%, respectively. The 90% confidence intervals were within ${\pm}20%$ (e.g., $-5.84{\sim}10.21,\;-17.11{\sim}5.18\;and\;-5.35{\sim}12.33\;for\;AUC_t,\;C_{max}\;and\;T_{max}$, respectively). There were no sequence effect between two tablets in logarithmically transformed $AUC_t\;and\;C_{max}$. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log(0.8) to log(1.25) (e.g., $0.94{\sim}1.10\;and\;0.85{\sim}1.05\;for\;AUC_t\;and\;C_{max}$, respectively). Two parameters met the criteria of prior and revised KFDA guideline for bioequivalence, indicating that $Alpit^{TM}$ tablet is bioequivalent to $Algiron^{TM}$ tablet.

• Biomolecules & Therapeutics
• /
• v.8 no.1
• /
• pp.32-37
• /
• 2000

Recently new soybean saponins with D DMP (2,5-dihydroxy-6-methyl-2,3,- dihydro-4H-pyran-4-one) moiety have been isolated from legumes. The purpose of this study is to characterize ROS scavenging activities of DDMP saponins ($\alpha$g, $\beta$g saponin) isolated from Glycine max (L.) Merrill. The scavenging activity on OH was examined in terms of lipid peroxidation in the rat liver homogenates and the same activity on $O_2$ was also determined in the xanthine-xanthine oxidase system, respectively. Up to 0.25 mg DDMP saponins ($\alpha$g and $\beta$g saponins) did not cause any significant effects on the prevention of lipid peroxidation as compared with the control group. In terms of superoxide scavenging activities, 0.25 and 0.5 mg $\alpha$g saponin inhibits only 2.6% and 5.5% (p<0.05) of the control group, respectively. However, $\alpha$g saponin dose-dependently (p<0.01, r=0.955) inhibits the formation of superoxide radical unto 21.3% of the control group with a maximal dose of 0.5 mg (p<0.01), equivalent to 0.17 units of superoxide dismutase activity.

• Microbiology and Biotechnology Letters
• /
• v.30 no.4
• /
• pp.395-401
• /
• 2002

Methyl ethyl ketone (MEK) and methyl isobutyl ketone (MIBK) have been widely used as solvents in various industries. Biodegradation of MEK and MIBK by Pseudomonas putida KT-3, which could utilize MEK or MIBK as a sole carbon source, was characterized, and the cosubstrate interaction in MEK/MIBK mixture was also studied. Within the range of initial MEK concentration (from 0.5 to 5.5 mM), an increased substrate concentration increased the specific degradation rate of MEK by P putida KT-3 (from 3.15 to 10.58 mmol/g DCW$\cdot$h), but the rate sightly increased at 11.0 mM of initial MEK concentation (11.28 mmol/g DCW$\cdot$h). The similar degradation rates of MIBK (4.69-4.92 mmol/g DCW$\cdot$h) were obtained at more than 3.0 mM of initial MIBK concentation. Kinetic analysis on the degradation of MEK/MIBK mixture by P. putida KT-3 showed that MEK or MIBK acted as a competitive inhibitor. Maximum degradation rate ($V_{max}$), saturation constant ($K_{m}$) and inhibition constant ($K_{1}$) were as follows: $V_{max,MEK}$=12.94 mmol/g DCW$\cdot$h; $K_{m,MEK}$=1.72 mmol/L; $K_{l,MEK}$=1.30 mmol/L; $V_{max,MIBK}$=5.00 mmol/g-DCW$\cdot$h; $K_{m,MIBK}$=0.42 mmol/L; $K_{l,MEK}$=0.77 mmol/L.

• Bulletin of the Korean Mathematical Society
• /
• v.59 no.3
• /
• pp.685-695
• /
• 2022

The minimum number of complete bipartite subgraphs needed to partition the edges of a graph G is denoted by b(G). A known lower bound on b(G) states that b(G) ≥ max{p(G), q(G)}, where p(G) and q(G) are the numbers of positive and negative eigenvalues of the adjacency matrix of G, respectively. When equality is attained, G is said to be eigensharp and when b(G) = max{p(G), q(G)} + 1, G is called an almost eigensharp graph. In this paper, we investigate the eigensharpness and almost eigensharpness of lexicographic products of some graphs.

• Physical Therapy Korea
• /
• v.22 no.1
• /
• pp.1-8
• /
• 2015

The purpose of this study was to compare the change in electromyography (EMG) activity in the gluteus maximus (G-max) and the gluteus medius (G-med) in subjects with and without chronic ankle instability (CAI) during three functional postures. Twenty four females were recruited for this study. Subjects were assigned into two groups: with CAI ($n_1=12$) and without CAI ($n_2=12$). The assessment postures were rotational squat, one leg stand above a gradient and crossed leg-sway. Electromyographic activities of the G-max and the G-med were recorded using surface EMG and was normalized using the maximal voluntary isometric contraction elicited using a manual muscle testing. Independent t-test was used to determine the statistical differences between two groups during the three functional postures. The comparisons of the three posture between two groups were performed using a one-way repeated analysis of variance. A Bonferroni adjustment used for post hoc analysis. The activation of EMG on G-max performing the one leg stand above a gradient and crossed leg-sway in subjects with CAI is significantly higher than normal group (p<.05). The activation of EMG on the G-max during the rotational squat was significantly increased, compared to those of the one leg stand above a gradient and crossed leg-sway (p<.05). The activation of EMG on G-med performing three exercise at CAI is significantly higher than normal group (p<.05). The activation of EMG on the G-med during the crossed leg-sway was significantly increased, compared to the rotational squat (p<.05). This study provides valuable information for clinician who research CAI.